Arthritis Mutilans

  • Amir Haddad
  • Vinod ChandranEmail author
Part of the following topical collections:
  1. Topical Collection on Psoriatic Arthritis


Arthritis mutilans is described as the most severe form of psoriatic arthritis. It is characterized by digital shortening associated with severe osteolysis of peripheral joints. Research on arthritis mutilans has been impeded by lack of an accepted case definition. Here we describe the definitions used to date, epidemiology, clinical and radiological features, and clues to pathogenesis of arthritis mutilans. An initiative by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to develop a consensus definition is described. The purpose of the GRAPPA initiative is to assist studies identifying clinical predictors and biomarkers for arthritis mutilans, so that patients at risk are identified early and appropriate therapeutic intervention is instituted to prevent joint destruction and preserve quality of life and function.


Psoriasis Arthritis mutilans Psoriatic arthritis mutilans Osteolysis Ankylosis Epidemiology Case definition Clinical features Radiographic features Pathogenesis 



Vinod Chandran is supported by Canadian Institutes of Health Research (CIHR) through a New Emerging Team grant. The University of Toronto Psoriatic Arthritis program is supported by the CIHR, The Arthritis Society, and the Krembil Foundation.

Conflict of Interest

Amir Haddad’s fellowship is supported by a grant from Janssen Canada.

Vinod Chandran declares that he has no conflict of interest.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Yoshida M, Belt EA, Kaarela K, et al. Prevalence of mutilans-like hand deformities in patients with seropositive rheumatoid arthritis. A prospective 20-year study. Scand J Rheumatol. 1999;28:38–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Belt EA, Kaarela K, Kauppi MJ, et al. Assessment of mutilans-like hand deformities in chronic inflammatory joint diseases. A radiographic study of 52 patients. Ann Rheum Dis. 1999;58:250–2.PubMedCrossRefGoogle Scholar
  3. 3.
    Wright V, Moll JMH. Seronegative Polyarthritis. Amsterdam: North Holland Publishing Co.; 1976.Google Scholar
  4. 4.
    Falcini F, Cimaz R. Juvenile rheumatoid arthritis. Curr Opin Rheumatol. 2000;12:415–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sato T, Ozawa T, Kikuchi M, et al. A case of progressive systemic sclerosis associated with mutilans-type arthropathy and suspected Felty’s syndrome. Ryumachi. 1990;30:53–9.PubMedGoogle Scholar
  6. 6.
    Aliu O, Netscher DT, Peltier M. Failure of small joint arthrodesis from resorption around a compression screw in a patient with lupus-associated arthritis mutilans: case report. Hand (N Y). 2008;3:72–5.CrossRefGoogle Scholar
  7. 7.
    Gold RH, Bassett LW, Seeger LL. The other arthritides. Roentgenologic features of osteoarthritis, erosive osteoarthritis, ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, multicentric reticulohistiocytosis, and progressive systemic sclerosis. Radiol Clin N Am. 1988;26:1195–212.PubMedGoogle Scholar
  8. 8.
    Swezey RL, Bjarnason DM, Alexander SJ, Forrester DB. Resorptive arthropathy and the opera-glass hand syndrome. Semin Arthritis Rheum. 1972–1973;2:191–244.CrossRefGoogle Scholar
  9. 9.
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.PubMedCrossRefGoogle Scholar
  10. 10.
    Biurdillon C. Psoriasis et arthropathies. These de Paris, No. 328,1888.Google Scholar
  11. 11.
    Marie P, Léri A. Une variete rare de rhumatisme chronique: La main en lorgnette. Bull Soc Med Hosp Paris. 1913;36:104–7.Google Scholar
  12. 12.
    Wright V. Psoriasis and arthritis. Ann Rheum Dis. 1956;15:348–56.PubMedCrossRefGoogle Scholar
  13. 13.
    Baker H, Golding DN, Thompson M. Psoriasis and arthritis. Ann Intern Med. 1963;58:909–25.PubMedGoogle Scholar
  14. 14.
    Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med. 1987;62:127–41.PubMedGoogle Scholar
  15. 15.
    Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14–7.PubMedCrossRefGoogle Scholar
  16. 16.
    • Gudbjornsson B, Ejstrup L, Gran JT, et al. Psoriatic Arthritis Mutilans in the Nordic countries; demographics and disease status. Scand J Rheumatol. 2012;41(Suppl 126):66. This study reports the prevalence, demographics and clinical characteristics of psoriatic arthritis mutilans in the Nordic countries.Google Scholar
  17. 17.
    Moll JM. The clinical spectrum of psoriatic arthritis. Clin Orthop Relat Res. 1979;143:66–75.PubMedGoogle Scholar
  18. 18.
    Marsal S, Armadans-Gil L, Martínez M, et al. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford). 1999;38:332–7.CrossRefGoogle Scholar
  19. 19.
    McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999;42:1080–6. Erratum in. Arthritis Rheum. 1999;42:1997.CrossRefGoogle Scholar
  20. 20.
    Ly J, Pinto C, Doyle A, Dalbeth N, McQueen FM. Axial bone proliferation causing cervical myelopathy in the mutilans form of psoriatic arthritis despite peripheral bone erosion. Ann Rheum Dis. 2009;68:443–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Tan YM, Østergaard M, Doyle A, et al. MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Res Ther. 2009;11:R2.PubMedCrossRefGoogle Scholar
  22. 22.
    McQueen F, Lloyd R, Doyle A, et al. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Ann Rheum Dis. 2011;70:1091–4.PubMedCrossRefGoogle Scholar
  23. 23.
    • Chandran V, Thavaneswaran A, Pellett FJ, Gladman DD. The association between Human Leukocyte Antigen and Killer-cell Immunoglobulin-like receptor gene variants and the development of arthritis mutilans in patients with psoriatic arthritis. Arthritis Rheum. 2011;63:S532. This study identified HLA and KIR polymorphisms associated with development of arthritis mutilans in patients with psoriatic arthritis.Google Scholar
  24. 24.
    Chandran V, Cook RJ, Thavaneswaran A, et al. Parametric survival analysis as well as multi-state analysis confirms the association between Human Leukocyte Antigen alleles and the development of Arthritis Mutilans in patients with psoriatic arthritis. J Rheumatol. 2012;39(8):1723.Google Scholar
  25. 25.
    Rahman P, Gladman DD, Cook RJ, et al. Radiological assessment in psoriatic arthritis. Brit J Rheumatol. 1998;37:760–5.CrossRefGoogle Scholar
  26. 26.
    • Rodriguez-Moreno J, Bonet M, Del Blanco-Barnusell J, et al. Mutilating/resorptive arthritis. A study of 24 patients in a series of 360 patients with psoriatic arthritis. Rheumatol Clin 2012 Dec 12. doi:pii: S1699-258X(12)00216-1. This multicenter cross sectional study described demographic and clinical features of arthritis mutilans and its possible association with nodular hand osteoarthritis.Google Scholar
  27. 27.
    Pomerantz RG, Mody E, Husni ME, Qureshi AA. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. J Drugs Dermatol. 2009;8:406–12.PubMedGoogle Scholar
  28. 28.
    Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis. 2007;66:370–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007;66:778–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Anandarajah AP, Schwarz EM, Totterman S, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67:296–301.PubMedCrossRefGoogle Scholar
  31. 31.
    Gladman DD. Psoriatic arthritis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford Textbook of Rheumatology. London: Oxford University Press; 1993. p. 691–698.Google Scholar
  32. 32.
    • Dalbeth N, Pool B, Smith T, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther. 2010;12:R164. This paper reported soluble and circulating biomarkers correlated with radiographic change in PsA. Mediators that could promote osteoclastogenesis in patients with PsA and thus potentially cause arthritis mutilans were identified.PubMedCrossRefGoogle Scholar
  33. 33.
    Mensah KA, Schwarz EM, Ritchlin CT. Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep. 2008;10:311–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Ritchlin CT, Quershi AA, de Vlam K, et al. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010;37:462–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Lambova SN, Müller-Ladner U. Capillaroscopic pattern in inflammatory arthritis. Microvasc Res. 2012;83:318–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis. 2006;65 Suppl 3:iii22–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Candia L, Cuellar ML, Marlowe SM, et al. Charcot-like arthropathy: a newly-recognized subset of psoriatic arthritis. Clin Exp Rheumatol. 2006;24:172–5.PubMedGoogle Scholar
  38. 38.
    • Haddad A, Thavaneswaran A, Gladman DD, Chandran V. Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis. Arthritis Rheum. 2012;64:S590–91. This longitudinal study describes the prevalence, characteristics and disease association of various forms of severe joint damage, including ankylosis and osteolysis, in a cohort of patients with early PsA.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western HospitalUniversity Health NetworkTorontoCanada
  3. 3.1E 416, Toronto Western HospitalTorontoCanada

Personalised recommendations